抗-NMI 兔抗

NMI (N-myc and STAT interactor) protein was initially identified in a yeast two-hybrid system, and is a homolog of interferon (IFN)-inducible protein IFP 35. It contains an Nmi/IFP 35 domain (NID), formed of 90-95 amino acids, and is responsible for NMI-NMI interactions and its localization within the cell. Its N-terminal contains the binding site for Myc-family proteins and other transcription factors. This protein is localized to human chromosome 22q13.3.

N-myc-interactor recombinant protein epitope signature tag (PrEST)

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

NMI (N-myc and STAT interactor) interacts with interferon (IFN)-inducible protein IFP 35 to form a protein complex, and thus, prevents the degration of IFP 35 by proteasome. Therefore, it amplifies the effects of IFNs by stabilizing IFP 35 protein. It acts as a tumor suppressor in breast cancer, where its expression is down-regulated. Up-regulation of this gene in aggressive breast cancer cell lines, results in inhibition of Wnt/β-catenin signaling, leading to retardation of tumor growth. It is also involved in the tumorigenesis of glioma, and variants of this gene are linked to susceptibility to gliomas.

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Corresponding Antigen APREST70910

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.